Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs Snowflake Inc (SNOW) Price & Performance

CVS Health CorpTrade
Snowflake IncTrade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs Snowflake Inc — how do they compare? CVS Health Corp trades at $86.2 (market cap $112.49B), while Snowflake Inc trades at $345 (market cap $117.43B). The key difference: CVS Health Corp and Snowflake Inc are close in size by market cap, and CVS Health Corp pays a 3.02% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Snowflake Inc for 54 Days on average.

CVSSNOW
Market Cap
$112.49B$117.43B
Volume
8,467,3922,441,528
Sector
HealthTechnology
52-Week High
$110.60$356.47
52-Week Low
$70.08$121.11
Typical Hold Time
83 Days54 Days
Enterprise Value
$174.83B$117.85B
Dividend Yield
3.02%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.

CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.

Snowflake Inc

SNOW trades at $343.4, up 2.22% on the day, with a neutral technical signal and bullish moving averages. Revenue growth is strong, reaching $3.63B in 2025, but the company remains unprofitable with a net income margin of -20.07%. Recent news highlights a $3.75B convertible note offering and positive analyst coverage, with 81% of analysts rating it a Buy and a consensus price target of $418.03.

The outlook is mixed: robust revenue expansion and strategic partnerships offer upside, but persistent losses, high valuation multiples, and dilution risks from the note issuance pose significant challenges. Investor sentiment is cautiously optimistic, hinging on future profitability improvements.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CVS

No sentiment data available yet.

SNOW
19% Buy81% Sell
Avg holding period · 54 Days

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS →

About Snowflake Inc

Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.

Read more on SNOW →